Drug Profile
Research programme: human polyclonal antibodies - Alere/Medarex/PDL BioPharma
Alternative Names: Human polyclonal antibodies research programme - Alere/Medarex/Protein Design LabsLatest Information Update: 05 Oct 2017
Price :
$50
*
At a glance
- Originator Biosite; Medarex; PDL BioPharma
- Class Polyclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 29 Sep 2017 Alere has been acquired by Abbott
- 03 Jul 2006 No development reported - Preclinical for Cancer in USA (unspecified route)
- 09 Jan 2006 Protein Design Labs is now called PDL BioPharma